|
| 应用FRAX评价乳腺癌术后患者骨折风险的临床研究 |
| The clinical study of application of FRAX in predicting the fracture risk in postoperative patients with breast cancer |
| |
| DOI：10.3969/j.issn.1006-7108.2021.01.021 |
| 中文关键词: 骨折风险评估工具 骨质疏松 乳腺癌 骨密度 |
| 英文关键词:fracture risk assessment tool osteoporosis breast cancer bone mineral density |
| 基金项目:江苏“六大人才高峰”高层次人才基金项目（WSW169）；国际课题“IOF对骨量减少人群骨折风险评估（FRAX）前瞻性研究”（IOFCJO-D001） |
|
| 摘要点击次数: 459 |
| 全文下载次数: 422 |
| 中文摘要: |
| 目的 应用骨折风险评估工具（fracture risk assessment tool，FRAX）评价乳腺癌术后患者骨折风险的临床研究。方法 选取2017年3月至2019年8月在连云港市第一人民医院接受过手术治疗的Ⅰ期至Ⅲ期乳腺癌女性181例作为观察组，并选取181例年龄和身体质量指数匹配的非乳腺癌女性作为对照组，收集个人基本信息、骨折风险因素、股骨颈骨密度（bone mineral density，BMD）及治疗方式等资料，比较不同组间的骨折风险，并进行骨折风险与临床因素的回归分析。结果 （1）乳腺癌术后患者10年内主要部位骨质疏松性骨折概率（probability of major osteoporotic fracture，PMOF）和10年内髋部骨折概率（probability of hip fracture，PHF）较对照组无显著增加（P=0.570、0.582）；（2）PMOF在芳香化酶抑制剂组最高，他莫昔芬组最低（P＜0.05）。芳香化酶抑制剂组的PHF显著高于单纯化疗组和他莫昔芬组（P＜0.05）；（3）回归分析显示，年龄、股骨颈BMD、骨折史、父母髋部骨折史和激素应用史对PMOF的影响具有统计学意义（P＜0.05）。年龄、股骨颈BMD、骨折史对PHF的影响具有统计学意义（P＜0.05）。结论 应用FRAX工具评估乳腺癌术后患者的骨折风险尚需进一步研究。 |
| 英文摘要: |
| Objective To investigate the fracture risk of postoperative patients with breast cancer by the FRAX tool. Methods A total of 181 female postoperative patients with stage Ⅰ to Ⅲ breast cancer in Lianyungang First People's Hospital from March 2017 to Augest 2019 were recruited as observation group. Meanwhile, 181 females without breast cancer who were adjusted for age and body mass index were chosen as control group. Personal information, fracture risk factors, and bone mineral density (BMD) of the femoral neck were collected. Fracture risk was compared between the groups. Regression analysis was performed between fracture risk and clinical factors. Results (1) The 10-year probability of major osteoporotic fracture (PMOF) and 10-year probability of hip fracture (PHF) in postoperative patients with breast cancer did not significantly increase compared with those in the control group (P=0.570, 0.582). (2) The aromatase inhibitor group had the highest PMOF, and the tamoxifen group had the lowest (P＜0.05). PHF was significantly higher in the aromatase inhibitor group than that in the conventional chemotherapy group and the tamoxifen group (P＜0.05). (3) Regression analysis revealed that age, femoral neck BMD, fracture history, parental hip fracture history, and steroid use history had statistically significant effects on PMOF (P<0.05). Age, femoral neck BMD, and fracture history had statistically significant effects on PHF (P<0.05). Conclusion Further studies are needed to assess the risk of fracture in postoperative patients with breast cancer using the FRAX tool. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |